Swiss National Bank Sells 75,200 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Swiss National Bank lessened its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 9.0% during the 2nd quarter, Holdings Channel reports. The firm owned 757,700 shares of the medical equipment provider’s stock after selling 75,200 shares during the period. Swiss National Bank’s holdings in Zimmer Biomet were worth $110,321,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the business. Cutler Group LLC CA bought a new stake in shares of Zimmer Biomet during the first quarter valued at approximately $25,000. Clear Street Markets LLC purchased a new position in Zimmer Biomet during the fourth quarter valued at $27,000. Horizon Bancorp Inc. IN lifted its stake in Zimmer Biomet by 1,483.3% in the 2nd quarter. Horizon Bancorp Inc. IN now owns 190 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 178 shares in the last quarter. Orion Capital Management LLC boosted its holdings in shares of Zimmer Biomet by 234.7% during the 1st quarter. Orion Capital Management LLC now owns 251 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 176 shares during the last quarter. Finally, Dark Forest Capital Management LP purchased a new position in shares of Zimmer Biomet during the first quarter valued at about $35,000. 87.48% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ZBH has been the subject of a number of research reports. Raymond James dropped their price target on Zimmer Biomet from $160.00 to $133.00 and set an “outperform” rating for the company in a research note on Thursday, November 9th. Citigroup cut their target price on shares of Zimmer Biomet from $146.00 to $125.00 and set a “neutral” rating for the company in a report on Monday, October 2nd. UBS Group upped their price target on shares of Zimmer Biomet from $116.00 to $125.00 in a research note on Wednesday, August 2nd. TheStreet cut shares of Zimmer Biomet from a “b-” rating to a “c+” rating in a research note on Friday, August 25th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Zimmer Biomet from $146.00 to $115.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 8th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $139.10.

Zimmer Biomet Trading Up 2.2 %

Shares of NYSE ZBH opened at $108.10 on Wednesday. The business’s 50 day moving average price is $110.89 and its 200-day moving average price is $125.52. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $102.00 and a fifty-two week high of $149.25. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.99 and a current ratio of 2.11. The company has a market cap of $22.59 billion, a price-to-earnings ratio of 47.83, a PEG ratio of 2.12 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Tuesday, November 7th. The medical equipment provider reported $1.65 earnings per share for the quarter, topping analysts’ consensus estimates of $1.59 by $0.06. The business had revenue of $1.75 billion for the quarter, compared to analyst estimates of $1.75 billion. Zimmer Biomet had a return on equity of 12.41% and a net margin of 6.52%. The business’s revenue was up 5.0% compared to the same quarter last year. During the same quarter last year, the firm posted $1.58 earnings per share. On average, sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 7.51 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, October 31st. Shareholders of record on Friday, September 29th were paid a $0.24 dividend. The ex-dividend date was Thursday, September 28th. This represents a $0.96 annualized dividend and a yield of 0.89%. Zimmer Biomet’s dividend payout ratio (DPR) is 42.48%.

Insiders Place Their Bets

In other Zimmer Biomet news, Director Sreelakshmi Kolli acquired 1,000 shares of the firm’s stock in a transaction dated Wednesday, August 30th. The stock was purchased at an average price of $120.37 per share, for a total transaction of $120,370.00. Following the acquisition, the director now owns 1,000 shares in the company, valued at approximately $120,370. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, Director Sreelakshmi Kolli acquired 1,000 shares of the business’s stock in a transaction dated Wednesday, August 30th. The shares were purchased at an average price of $120.37 per share, for a total transaction of $120,370.00. Following the completion of the acquisition, the director now directly owns 1,000 shares in the company, valued at approximately $120,370. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Michael W. Michelson bought 1,300 shares of the stock in a transaction that occurred on Friday, August 25th. The stock was bought at an average price of $115.50 per share, with a total value of $150,150.00. Following the completion of the purchase, the director now directly owns 3,385 shares in the company, valued at $390,967.50. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 5,300 shares of company stock valued at $619,090. 0.95% of the stock is currently owned by insiders.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.